07-11-13 *CO-OEDIT News* OEDIT announces Early Stage Bioscience Company grantees…
Posted by Brian Allmer on July 11, 2013
DENVER — Thursday, July 11, 2013 — The Colorado Office of Economic Development and International Trade today announced the recipients of the Bioscience Discovery Evaluation Grant Program’s Early Stage grants. The grants will support work that is critical in moving these early stage companies forward in commercializing novel Colorado bio-technologies.
• Membrane Protective Technologies – filtration device for GameteGuard, which is a novel method to counteract fertility decline in cattle (associated research institution University of Northern Colorado). $50,000 award
• SixOne Solutions LLC – Optimized Eya2 inhibitors for treating breast cancer (associated research institution University of Colorado). $50,000 award
• SmartMove – Technology for footwear-based physical monitoring (associated research institution University of Colorado). $200,000 award
• Tissue Fusion – developing laser-based medical devices to fuse tissues together as an alternative to sutures or staples (associated research institution University of Colorado). $75,000 award
• Xalud Therapeutics – development of a first-in-class multiple sclerosis treatment (associated research institution University of Colorado). $222,000 award
“We are pleased with these latest grant award winners and expect to see great progress from them in the near future,” said Sonya Guram, Bioscience Program Manager at the Colorado Office of Economic Development and International Trade. “State funding will support product development and testing, as well as business development needs, for these companies. We hope to see commercial products from them down the line.”
The Early-Stage Bioscience Company grants under the Bioscience Discovery Evaluation Grant Program are intended to spur economic development by helping new companies, born out of Colorado research institutions, succeed in turning novel technologies into successful products and services. Grants, up to $250,000, are available to qualified Early-Stage Companies whose technology is licensed from a qualified research institution. Grants support the commercialization of bioscience technologies with applications in therapeutic or diagnostic products, devices, or instruments to improve human health, agriculture or biofuels.